Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.4.3.13 (
lysyl oxidase
)
1,248
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The transcriptional activator IFN regulatory factor 1 (IRF-1) and its antagonistic repressor
IRF-2
are regulators of the IFN system. IRF-1 also manifests tumor suppressive activity, and its inactivation could contribute to the development of human hematopoietic malignancies. Here, we report the identification of the
lysyl oxidase
gene as a target gene of IRF-1. An IRF response element was identified in the
lysyl oxidase
gene promoter. We also demonstrate that the transformed phenotype of ras-expressing embryonic fibroblasts with a null mutation in the IRF-1 allele could be suppressed by the expression of the
lysyl oxidase
cDNA, implicating its potential role in tumor suppression. Thus, the regulation of the
lysyl oxidase
gene by IRF-1 could contribute to the multistep process of malignant transformation.
...
PMID:Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression. 862 21
Lysyl oxidase is an extracellular enzyme involved in connective tissue maturation that also acts as a phenotypic suppressor of the ras oncogene. To understand how this suppressor is controlled, gene transcription was studied and the promoter was characterized. Nuclear runoff transcription assays indicated that the markedly reduced amounts of
lysyl oxidase
message detected after ras transformation resulted from inhibition of
lysyl oxidase
transcription. Interferon-mediated phenotypic reversion of ras transformed cells, in which the ras oncogene continued to be expressed, was accompanied by the restoration of
lysyl oxidase
transcription. Reporter gene assay of a transfected mouse
lysyl oxidase
promoter indicated that it was active in the transformed background, despite the silencing of the endogenous
lysyl oxidase
promoter. The detection of comparable amounts of mRNA for transcription factors IRF-1 and
IRF-2
in normal and ras-transformed cell lines suggests that the differential transcription of
lysyl oxidase
was not due to regulation of IRFs. Lysyl oxidase promoter activity was localized to a 126 bp region that includes two consensus TATA boxes with associated confirmed cap signals. Analysis of a human
lysyl oxidase
promoter sequence indicated similar promoter elements and extensive sequence identity with the mouse promoter. The binding of transcription factor AP2 to sites predicted in the control region was confirmed by DNase footprinting. Lysyl oxidase transcription was stimulated by dexamethasone treatment of cells, but this effect could not be assigned within the approximately 3 kb region tested in reporter gene constructs. The promoter activity of the
lysyl oxidase
reporter gene construct was completely abolished by in vitro DNA methylation, suggesting that the transcriptional suppression after transformation by the ras oncogene may involve DNA methylation.
...
PMID:Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene. 1039 Nov 27